The Association of Omentin and Ischemic Stroke
Launched by XI'AN NO.3 HOSPITAL · Apr 21, 2017
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the connection between a substance called omentin and ischemic stroke, which is a type of stroke caused by a blockage of blood flow to the brain. Researchers want to find out if omentin is related to how often strokes happen, how severe they are, and how well people recover after having one. The study is currently looking for participants, and anyone can join, regardless of gender.
To be eligible for the study, individuals must have had an acute ischemic stroke for the stroke group. For the control group, participants should not have any history of stroke. People with a different type of stroke called hemorrhagic stroke or those who have had a previous ischemic stroke cannot participate. Additionally, anyone expected to live less than three more years will not be included in the study. Participants can expect to be part of an important investigation that could help improve understanding of strokes and recovery in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • For ischemic stroke group,acute clinically defined ischemic stroke
- • For control group, without any history of stroke
- Exclusion Criteria:
- • For ischemic stroke group
- • Hemorrhagic Stroke
- • Previous Ischemic Stroke For control group
- • The expected life expense less than 3 years
About Xi'an No.3 Hospital
Xi'an No. 3 Hospital is a leading medical institution in Xi'an, China, recognized for its commitment to advancing healthcare through innovative research and clinical excellence. With a focus on a wide range of medical specialties, the hospital plays a pivotal role in conducting clinical trials that aim to enhance treatment outcomes and patient care. Its state-of-the-art facilities and a team of experienced healthcare professionals enable the hospital to rigorously evaluate new therapies and interventions, contributing to the global body of medical knowledge and improving health services for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shanxi, China
Patients applied
Trial Officials
Tian Ye, PhD
Principal Investigator
Xi'an No.3 Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials